Indexed in

License and use

Citations

Cited 18 times in

Altmetrics

Analysis of institutional authors

Share

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

Publicated to:Journal of Cystic Fibrosis. 21 (4): e221-e231 - 2022-07-01 21(4), DOI: 10.1016/j.jcf.2022.06.006

Authors: Carr SB; McClenaghan E; Elbert A; Faro A; Cosgriff R; Abdrakhmanov O; Brownlee K; Burgel PR; Byrnes CA; Cheng SY; Colombo C; Corvol H; Daneau G; Goss CH; Gulmans V; Gutierrez H; Harutyunyan S; Helmick M; Jung A; Kashirskaya N; McKone E; Melo J; Middleton PG; Mondejar-Lopez P; de Monestrol I; Nährlich L; Padoan R; Parker M; Pastor-Vivero MD; Rizvi S; Ruseckaite R; Salvatore M; da Silva-Filho LVRF; Versmessen N; Zampoli M; Marshall BC; Stephenson AL; Bell SC; Reid D; Wark P; Van Braeckel E; Gohy S; Knoop C; Pirson J; De Wachter E; Dupont L; Hanssens L; Nowé V; Lequesne M; Athanazio RA; Meneses DG; Boussaud V; Brinchault G; Coirier-Duet E; Dubus JC; Grenet D; de Miranda S; Beaumont L; Kanaan R; Lauraens M; Martin C; Mittaine M; Prévotat A; Reynaud-Gaubert M; Sermet-Gaudelus I; Tatopoulos A; Chiron R; Dalphin ML; Gerardin M; Weiss L; Wizla N; Ramel S; Plant B; Gunaratnam C; Jackson A; de Winter- de Groot K; Luijk B; Wesseling G; Kondratyeva E; Zhekayte E; Amelina E; Mukhina M; Simonova O; Alvarez-Fernandez A; Sole-Jover A; Cortell-Aznar I; Girón-Moreno R; López-Neyra A; Ramos-Cancelo I; Lázaro-Carrasco M; Vivero DP; de Valbuena MR; Prados-Sanchez C; Costa-Colomer J; Gartner S; Diab-Caceres L; Gilljam M; Lindberg U; Diemer S; Allenby M

Affiliations

Abstract

Background: This international study aimed to characterise the impact of acute SARS-CoV-2 infection in people with cystic fibrosis and investigate factors associated with severe outcomes. Methods Data from 22 countries prior to 13th December 2020 and the introduction of vaccines were included. It was de-identified and included patient demographics, clinical characteristics, treatments, outcomes and sequalae following SARS-CoV-2 infection. Multivariable logistic regression was used to investigate factors associated with clinical progression to severe COVID-19, using the primary outcome of hospitalisation with supplemental oxygen. Results: SARS-CoV-2 was reported in 1555 people with CF, 1452 were included in the analysis. One third were aged <18 years, and 9.4% were solid-organ transplant recipients. 74.5% were symptomatic and 22% were admitted to hospital. In the non-transplanted cohort, 39.5% of patients with ppFEV1<40% were hospitalised with oxygen verses 3.2% with ppFEV >70%: a 17-fold increase in odds. Worse outcomes were independently associated with older age, non-white race, underweight body mass index, and CF-related diabetes. Prescription of highly effective CFTR modulator therapies was associated with a significantly reduced odds of being hospitalised with oxygen (AOR 0.43 95%CI 0.31-0.60 p<0.001). Transplanted patients were hospitalised with supplemental oxygen therapy (21.9%) more often than non-transplanted (8.8%) and was independently associated with the primary outcome (Adjusted OR 2.45 95%CI 1.27-4.71 p=0.007). Conclusions: This is the first study to show that there is a protective effect from the use of CFTR modulator therapy and that people with CF from an ethnic minority are at more risk of severe infection with SARS-CoV-2.

Keywords